GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Drugs Made In America Acquisition DMAA · USD

N/A · US listing · 🇺🇸 United States

Compare

10.89

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

$5.9m

FY2024FY2025

Free cash flow

−$539,187

FY2024FY2025

Shareholders' equity

$232.6m

FY2024FY2025

Income statement

Fiscal years

FY2025FY2024
Operating income−$2.8m−$479
Net income$5.9m−$479
Diluted earnings per share0.18-0.00

Balance sheet

At each fiscal year end

FY2025FY2024
Total assets$239.9m$551
Cash and short-term investments$6,137$1,351
Total liabilities$7.3m$796
Debt—$662,300
Shareholders' equity$232.6m−$244
Shares outstanding34m9m

Cash flow

Fiscal years

FY2025FY2024
Cash from operations−$539,187−$172,265
Capital spending—−$5
Free cash flow−$539,187−$172,270

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$136,934−$143,301−$2.1m−$263,703−$131,919−$330,925−$279−$144,928
Net income$1.7m$2.0m$212,958$2.2m$2.3m$1.3m−$279−$144,928
Diluted earnings per share0.090.100.010.060.070.04-0.00-0.02
Total assets$146.9m$242.0m$239.9m$237.6m$235.2m$232.8m$551$426,139
Cash and short-term investments$20,280$14,887—$717$822$923$1,351$2,095
Debt—$100,000———$60,898$662$552,015
Shareholders' equity−$7.4m$234.6m$232.6m$230.3m$228.0m$225.6m−$244−$164,859

Valuation history

At each fiscal year end

FY2025
Price to earnings58.9

Share price return

Finished calendar years

2025
Return4%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.